Introduction

EryDel mission is to develop new innovative therapies

EryDel (acronym of ERYthrocyte DELivery) S.p.A. is a company operating in the pharmaceutical field developing products with a proprietary technology.

EryDel is a company focused on developing and commercializing of innovative therapies and diagnostic tools based on the use of autologous red blood cells as agent carriers, selective drug targeting system, agent passive reservoirs and circulating bioreactors.

The company owns a proprietary technology that allow to encapsulate any kind of active agents within a small quantity of autologous blood with automatic, reliable and a reproducible system.

EryDel is developing its own new therapies and is collaborating with partners for exploiting the possibility to encapsulate their own agents into autologous red blood cells.

News

08/10/2010 » EryDel at BIOTECHNICA 2010 in Hannover » view

13/09/2010 » EryDel has CE Marked its New Medical Devices for automatic encapsulation of Drugs into Human Autologous Red Blood Cells » view

14/01/2010 » Erydel will be present at Biosquare Forum Congress in Geneva » view

Clinical Trial CRODEX01 for CROHN steroid dependent patients » view

23/09/2009 » EryDel posted an IBox-out at Innoget.com » view

16/09/2009 » EryDel has been added to the Tornado Insider Radar Database, The source for Europe's high-growth high-tech community! » view

15-06-2009 » EryDel at Healthcare Innovation Tournment in Barcelona
EryDel, finalist of the Healthcare Innovation Tournament at HiT Barcelona’09

EryDel SPA
2009 © All right reserved